Akero is a clinical-stage company founded to develop transformational treatments for patients with serious metabolic diseases marked by high unmet medical need.

We began with an engineered protein called efruxifermin (EFX), which we licensed from Amgen and are developing for treatment of metabolic dysfunction-associated steatohepatitis (MASH). MASH is a serious liver disease caused by metabolic dysregulation. EFX is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body.